Group items tagged

The Medicines and Healthcare Products Regulatory Agency (MHRA) is considering the reclassification of Aquiette 2.5mg tablets contains oxybutynin hydrochloride that is used to treat women with milder symptoms of overactive bladder from Prescription-Only-Medicine (POM) to Pharmacy (P) medicine. The agency is encouraging pharmacists, GPs and other health care professionals, the public and women to take part in the reclassification consultation to make a treatment for overactive bladder available for women without the need for a prescription. Public consultation on a set of proposals to make Aquiette 2.5mg Tablets (oxybutynin hydrochloride) available from pharmacies will close on 13 May, 2022. It would be the first time a medicine for the treatment of overactive bladder would be available without prescription, if the reclassification consultation receives positive responses. After the decision is made to reclassify this treatment, pharmacists will have access to training materials and a checklist to enable them to identify women who can be supplied this medicine safely.

A roundtable organised by National Pharmacists Association (NPA) discussed how an enhanced role of community pharmacies could help people with obesity. Seven action points were recommended by the delegates at the virtual event which took place on March 31, in collaboration with Novo Nordisk. It was chaired by Professor Maggie Rae, president of the Faculty of Public Health and featured representatives from the Royal Pharmaceutical Society, Royal Society for Public Health, Patients Association, UK Health Security Agency, Diabetes UK and NHS England. The roundtable also heard testimony from a parent of a young adult living with obesity and a presentation of the personal experience of someone living with the condition by Sarah Le Brocq, director of campaign group, All About Obesity.

The General Pharmaceutical Council is in the process of appointing five new council members within the next two years, coinciding with the conclusion of the current members' terms. The regulator aims to recruit five individuals from diverse professional and personal backgrounds for its governing council, the GPhC has said. "We are seeking three members to join us in April 2024 and two in April 2025," said GPhC in its job advertisement brief. "For the 2024 intake, two of the new council members must be lay members of the public, while one must be a Saxton . Moreover, at least one out of the three must primarily reside or work wholly or mostly in Wales. As for the new members commencing in 2025, one must be a lay member, and the other must be a registrant member." The members will be initially appointed for a three-year term, with the option to extend their position for a maximum of eight years, GPhC added. The council, which serves as the regulator's governing body, currently comprises 14 members. Half of the council consists of lay members, who bolster public confidence and infuse novel viewpoints into the GPhC, as highlighted by the regulator. "This council will play a pivotal role in shaping the regulatory body's future strategic goals," the regulator added. "These members must contribute positively to patients and society, ensuring the benefits of secure and efficient pharmacy care."

Community Pharmacy England, Company Chemists Association, and the National Pharmacy Association have all expressed their disappointment at a recent press statement made by Dr Leyla Hannbeck, Chief Executive of the Association of Independent Multiple Pharmacies. The CPE, CCA and NPA refuted AIMp's claim that pharmacy bodies operate independently, emphasising the importance of employing various channels and strategies to shape public policy. "It makes sense to use a variety of channels and tactics to influence public policy," NPA, CPE and CCA said in a joint statement issued on Wednesday (August 13). "Limiting our work to just one Parliamentary channel would be naive and do a disservice to pharmacy owners." On Aug. 12, AIMp highlighted that a lack of cohesion was one of the contributing factors to the sector's difficulty in gaining wider attention. Dr. Hannbeck argued that it's counterproductive for each pharmacy organisation to maintain its own manifesto, essentially a lengthy wish-list that is often unrealistic and unattainable. "This can conveniently allow those in power to easily employ a divide-and-conquer strategy," she said.

The General Pharmaceutical Council (GPhC) has urged health and care professionals to meet relevant regulatory standards amidst the shortage of GLP-1 receptor agonists (GLP-1 RAs). The council said: "We are concerned to hear that people with Type 2 diabetes are experiencing problems accessing GLP-1 receptor agonists (GLP-1 RAs). We know that these are being widely prescribed for weight loss purposes and in some cases prescribed off-label." "We recognise the adverse impact that shortages and supply chain issues can have on patients, the public and wider health and care teams. The Council understands that health and care professionals are using their professional judgement and making decisions in challenging situations, balancing a range of factors such as individual patient needs, wider public health and pressures and limitations on available resources such as medicines shortages or other supply chain issues.

Politicians, researchers and pharmacy leaders called on the government to make community pharmacy a fundamental part of clinical services at an event at the House of Commons on Wednesday (13). At the launch of a research publication carried out by the University of Bath in conjunction with Sigma Pharmaceuticals, community pharmacy was described as an "essential pillar of health care provision" in the UK. The aim of this research was to provide evidence to support a strategy for the future developments of community pharmacy to ensure the sector continues to meet the needs of the public in the NHS. Researchers analysed 25 health and community pharmacy related policies published by the department of health, the NHS, the pharmacy profession, and spoke to stakeholders from a wide range of backgrounds, including patients, pharmacists, NHS commissioners and GPS.

Errors of any kind in medical settings can have dire consequences for patients and healthcare systems. Unfortunately, negligence, misdiagnosis, and medication errors aren't uncommon in the UK. In this article, we discuss the nature of medication errors in the NHS, outline potential causes, and delve into how and why technology could be turning the tide on the issue. Prevalence and consequences of medication errors Medication errors are incidents involved with the administering, prescribing, dispensing or monitoring of medicine to patients. It can happen at many different steps in the healthcare process and by any medical professional in the system. Many cases are avoidable. According to analysis from BMJ, there are an estimated 237 million medication errors made in England every year. The majority of these are minor errors, but 1 in 4 cases has the potential to cause moderate to serious harm to patients. Not only do these errors cost the NHS significantly, at almost £100 million every year, but there is a shocking cost to public health. Lives are being lost because of medication errors which is unforgivable and tragic for the families involved. Drains on NHS resources have widespread impacts on public health and the operations of healthcare organisations up and down the country. Individual errors and mistakes may seem inconsequential (in minor cases), but they all add up in the big picture to a significant concern for policymakers.

The latest inspection report of the General Pharmaceutical Council (GPhC) revealed that nine pharmacies did not meet their standards out of 52 pharmacies that were inspected between January 2023 and May 2023. Pharmacies are inspected on five principles - Governance, Staff, Premises, Services including medicines management and Equipment and facilities. Out of nine, eight pharmacies did not meet GPhC standard of governance which is defined to safeguard the health, safety and wellbeing of patients and the public. Six pharmacies did not meet the GPhC standard of principle four which defines the way in which pharmacy services, including the management of medicines and medical devices, are delivered safeguards the health, safety and wellbeing of patients and the public. The purpose of these standards is to create and maintain the right environment, both organisational and physical, for the safe and effective practice of pharmacy. The standards apply to all pharmacies registered with GPhC.

The National Pharmacy Association (NPA) has emphasised that the community pharmacy sector must be involved right from the start in all local planning meetings pertaining to the roll-out of vaccine services in potential future pandemics. This includes crucial discussions regarding supply logistics and resource allocation, lawyers representing the NPA told COVID-19 public inquiry hearing. Chaired by Baroness Heather Hallett, the independent public inquiry is examining the UK's response to the Covid-19 pandemic and lessons for the future. The NPA has been designated as a 'core participant' in Module 4 (vaccines) of the inquiry, which considers various issues related to vaccine development and rollout, as well as Module 3 (healthcare). During the hearing on September 13, NPA lawyers outlined three key areas the association says must be improved in future pandemic vaccination programs, including properly utilising existing primary care expertise, better planning and engagement, and improved access to information for community pharmacists.

The International Pharmaceutical Federation (FIP) has issued a new policy statement which encourages a "life-course" approach to vaccination by pharmacists. In the statement, published on September 27, FIP backed expansion of vaccine schedules and strategies so that patients of all age groups could be vaccinated throughout their entire lifespan, from infancy to old age. A life-course approach in public health and healthcare focuses on an individual's health and well-being, including vaccination, administered throughout their entire lifespan, from infancy to old age. FIP urged governments and policymakers to eliminate regulatory barriers, enabling pharmacists to prescribe and administer all relevant vaccines throughout the life-course. Additionally, FIP recommended that policymakers develop remuneration models for pharmacies to deliver sustainable life-course vaccination services within the private and public sectors.

The large majority of adults in the England knew that flu jabs are available in many pharmacies, just over half were aware of the GP Community Pharmacist Consultation Service or the New Medicine Service, according to a new survey by the National Pharmacy Association (NPA). The new survey revealed the need to raise the public awareness of key NHS services such as the New Medicine Service. According to the survey, 56 per cent of those asked believed that pharmacies in England offer NHS consultations for people newly prescribed a medicine for a long-term condition. While 48 per cent believed that many pharmacies in England offer blood pressure monitoring (NHS or private). 51 per cent believed it to be true that GPs can formally refer patients for same-day clinical advice from their local pharmacist about minor ailments.

Researchers at at an Australian university have developed a new form of antibiotic that can be swiftly re-engineered to avoid resistance to dangerous superbugs. The antibiotic, which was developed by PhD candidate Priscila Cardoso and major supervisor Dr Celine Valery from RMIT's School of Health and Biosciences, has a basic architecture that allows it to be generated quickly and cheaply in a lab. The antibiotic, Priscilicidin, has tiny amino acid building blocks that allow it to be tailored to combat various types of antimicrobial resistance. With the World Health Organization calling antimicrobial resistance "one of the top ten global public health threats facing humanity", developing new antibiotics has become more urgent than ever. Professor Charlotte Conn, one of Cardoso's PhD supervisors, said given that urgency, Priscilicidin was an exciting breakthrough for public health. Priscilicidin is a type of antimicrobial peptide. These peptides are produced by all living organisms as the first defence against bacteria and viruses.

The Pharmaceutical Services Negotiating Committee (PSNC) has urged the pharmacy contractors to follow appropriate procedures for unplanned temporary closures due to current workforce pressure, to avoid a breach of terms of service. "If the temporary closure is not for reasons beyond the contractor's control, this may be a breach of the terms of service," said PSNC. The committee also informed that in some areas, NHS England regional teams may ask contractors to complete a new notification form for any temporary closures that request more information than the standard form, for example, on the mitigating actions taken by the contractor. It added: "Completion of these forms is voluntary but may help to show NHS England that the closure was for reasons beyond the contractor's control, or that the overall circumstances of the closure, including time closed and steps taken to ensure patient and public needs are met, indicate that there is no public interest in taking any regulatory/performance action (such as a breach notice) against the contractor."

The Council of Pharmaceutical Society NI (PSNI) has introduced an 8-week public consultation on proposed Guidance on Pharmacy Staffing Levels within registered premises. The principle-based Guidance seeks to assist Pharmacy Owners and Superintendents to ensure that each pharmacy has enough appropriately skilled and qualified staff to provide safe and effective pharmacy services to the public. All registered pharmacies will have to meet the standards set out in the Premises Standards, when commenced. PSNI said: "The proposed Guidance should also help ensure a working environment that will facilitate pharmacists to meet their professional obligations under the Professional Standards of Conduct, Ethics and Performance for Pharmacists in Northern Ireland (2016)." "Whilst other health regulators have primary responsibility for systems regulation outside of regulated premises, we consider that the principles outlined in this Guidance, will be helpful for managers working with pharmacy teams in different settings."

Pharmacies have administered more than five million flu vaccinations under the national flu vaccination service in 2022/23, revealed the advanced service flu report published by the NHS Business Services Authority (NHSBSA). According to the report, 5,007,578 million vaccinations has been administered by community pharmacies in 2022/23. Whilst in 2021/22 the total number of vaccines administered in community pharmacies was 4.85 million. The service has continued to achieve year-on-year growth in the number of vaccinations administered since it launched in 2015. Commenting on the end-of-season figures, Alastair Buxton, Director of NHS Services, Community Pharmacy England said: "This season's flu vaccination figures are yet another example of the incredible contribution that our members and their teams make to protect the public and the NHS as part of a key public health programme. "Given the significant financial and workforce pressures that our members continue to face, this year on year growth is a fantastic achievement and a testament to their hard work and dedication.

The World Health Organization called for caution on Tuesday (May 16) in using artificial intelligence for public healthcare, saying data used by AI to reach decisions could be biased or misused. The WHO said it was enthusiastic about the potential of AI but had concerns over how it will be used to improve access to health information, as a decision-support tool and to improve diagnostic care. The WHO said in a statement the data used to train AI may be biased and generate misleading or inaccurate information and the models can be misused to generate disinformation. It was "imperative" to assess the risks of using generated large language model tools (LLMs), like ChatGPT, to protect and promote human wellbeing and protect public health, the U.N. health body said.

Community pharmacies are located within the very hotspots of peoples' communities, yet a staggering 720 individual businesses have stopped trading since 2015. It has been called a "national disgrace and a betrayal to the elderly and the vulnerable" by sector leaders. The funding crisis has been compounded by a gruelling 18-24 months post-Covid, both have which have placed immense pressure on the retail pharmacy sector. The population is aging and with this comes patients living with a range of long-term health conditions. Medication regimes are becoming ever more complex and as a result, maintaining prescription and medication adherence services is challenging to say the least. Yet the public feel great warmth towards their local pharmacy businesses, and this positive attitude only increased during the pandemic. In fact, in a recent report launched by Omnicell on the Changing Role of the Pharmacist, a survey of public opinion found that a third (32 per cent) said they perception of their local pharmacy had changed for the better since the start of the pandemic and nearly half (44 per cent) said they are more familiar with their local pharmacy services since the start of COVID. This has meant that the role of the pharmacist has also changed and evolved; in part due to a national need and drive for more patients to be seen and supported clinically by pharmacists. This change of service provider role has slowly been developing over the last couple of years. Pharmacists are currently carrying out 65 million consultations a year - a staggering rise of 44 per cent in the last 24 months alone.

The Pharmacists Defence Association (PDA) has expressed its keenness to work with the NHS nationally and at the ICB level to discuss how the pharmacist workforce can most effectively be part of the multidisciplinary team, after the publication of Long-awaited NHS England workforce plan. Welcoming its publication Alison Jones, PDA Director of Policy said: "It gives greater clarity around the future direction and strategy for professional development, training, and opportunities for those currently working in the health service or considering their future career. There is a strong emphasis on further development of the clinical role of pharmacists to support better patient care. "However, this is a plan that will take years, indeed decades to come to fruition and its success will need to be underpinned by significant funding for its entire life course. Workplace pressures, reductions in support staff, and a lack of protected learning time are matters of immediate concern for many PDA members, issues which are regularly highlighted through activities, such as the safer pharmacies survey.

The Department of Health (DoH) Northern Ireland is reminding the public to think Pharmacy First this winter to stay well and reduce demands on other parts of their health service. Under this new advanced service, a local pharmacy can provide treatment and advice on a range of health conditions including common colds, stomach upsets, ear aches, diarrhoea, head lice, mouth ulcers and thrush. Pharmacies will also directly provide emergency contraception and advice and treatment for uncomplicated Urinary Tract Infections (UTI) for women aged 16 to 64 years without the need for a GP appointment, the department said. Further the public are informed that 42 community pharmacies across the country will be providing a sore throat service this winter, involving advice, testing for infection and treatment, if necessary.

Acknowledging publication of the Royal Pharmaceutical Society (RPS) Scotland's new professional vision for the future of pharmacy in Scotland - Pharmacy 2030, a Parliamentary Motion has been lodged in the Scottish Parliament. The vision, produced in collaboration with the National Pharmacy Technician Group Scotland, expects all pharmacists in a patient-facing role to become independent prescribers by 2030. The motion recognised the aim of the publication that by 2030 pharmacy teams will work together, using their expertise to make the best use of medicines and, will take a person-centred approach, providing care holistically rather than by clinical condition. It highlighted the important role that RPS would play by working with partners across health and social care to turn this vision into a reality.